Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginInterest Coverage RatioInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

Serina Therapeutics (SER) Equity Average (2018 - 2025)

Serina Therapeutics (SER) has disclosed Equity Average for 8 consecutive years, with $778500.0 as the latest value for Q4 2025.

  • Quarterly Equity Average rose 111.69% to $778500.0 in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $778500.0 through Dec 2025, up 111.69% year-over-year, with the annual reading at $235500.0 for FY2025, 101.48% up from the prior year.
  • Equity Average hit $778500.0 in Q4 2025 for Serina Therapeutics, down from $1.6 million in the prior quarter.
  • In the past five years, Equity Average ranged from a high of $1.6 million in Q3 2025 to a low of -$36.9 million in Q1 2023.
  • Historically, Equity Average has averaged -$15.4 million across 5 years, with a median of -$12.1 million in 2022.
  • Biggest five-year swings in Equity Average: plummeted 612.89% in 2021 and later skyrocketed 111.69% in 2025.
  • Year by year, Equity Average stood at -$10.9 million in 2021, then crashed by 142.2% to -$26.5 million in 2022, then fell by 24.02% to -$32.8 million in 2023, then surged by 79.71% to -$6.7 million in 2024, then skyrocketed by 111.69% to $778500.0 in 2025.
  • Business Quant data shows Equity Average for SER at $778500.0 in Q4 2025, $1.6 million in Q3 2025, and $1.6 million in Q2 2025.